---
title: "Iproniazid - Depressive disorder"
sidebar: mydoc_sidebar
permalink: db04818-mesh-d003866-1.html
toc: false 
---


Path ID: `DB04818_MESH_D003866_1`
{% include image.html url="images/db04818-mesh-d003866-1.png" file="db04818-mesh-d003866-1.png" alt="db04818-mesh-d003866-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:D007490 | Iproniazid | Drug |
| InterPro:IPR001613 | Monoamine oxidase | GeneFamily |
| MESH:C044821 | Isopropylhydrazine | ChemicalSubstance |
| HP:0000716 | Depression | PhenotypicFeature |
| MESH:D003866 | Depressive disorder | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Iproniazid | DECREASES ACTIVITY OF | Monoamine Oxidase |
| Monoamine Oxidase | NEGATIVELY REGULATES | Depression |
| Iproniazid | HAS METABOLITE | Isopropylhydrazine |
| Isopropylhydrazine | DECREASES ACTIVITY OF | Monoamine Oxidase |
| Depression | CAUSES | Depressive Disorder |
|---------|-----------|---------|

Comment: Iproniazid is stated as Withdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine

Reference: [https://go.drugbank.com/drugs/DB04818#mechanism-of-action](https://go.drugbank.com/drugs/DB04818#mechanism-of-action){:target="_blank"}